Wednesday, February 10, 2010, 7:17AM AEST - The Australian Stockmarket opens in 2 hours and 43 minutes.
To create a watchlist or portfolio of shares, Register

Molecular Insight Pharmaceuticals, Inc. (MIPI)

6:59AM AEST: 1.2225 USD  Down 0.0275 (2.20%)  
 MORE ON MIPI 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Molecular Insight Pharmaceutica (NGM:MIPI) Delayed quote dataEdit
Last Trade:1.2225 USD
Trade Time: 6:59AM AEST
Change:Down 0.0275 (2.20%)
Prev Close:1.25
Open:1.24
Bid:1.22 x 4200
Ask:1.23 x 500
1y Target Est:7.17
Day's Range:1.21 - 1.27
52wk Range:1.15 - 7.90
Volume:55,096
Avg Vol (3m):129,369
Market Cap:30.85M
P/E (ttm):N/A
EPS (ttm):-2.75
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add MIPI to Portfolio   Download Data

 HEADLINES 
MOLECULAR INSIGHT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD
EDGAR Online (Thu, Jan 28)
Molecular Insight Announces Updates to Board of Directors
Marketwire (Thu, Jan 28)
UPDATE - Molecular Insight cuts job, shares fall
at Reuters (Tue, Jan 12)
Biotech's Latest Failed Trials, Missed Targets
at Seeking Alpha (Mon, Jan 11)
Molecular Insight Pharmaceuticals Announces Personnel Reduction to Align Operations With Development Activities
Marketwire (Fri, Jan 8)
Cashing In on Obamacare
at Motley Fool (Fri, Dec 18)
Molecular Insight Pharma downgraded by Jefferies & Co
Briefing.com (Fri, Dec 11)
MOLECULAR INSIGHT PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibi
EDGAR Online (Fri, Dec 4)
MOLECULAR INSIGHT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD
EDGAR Online (Wed, Nov 25)
Molecular Insight Pharmaceuticals Announces Changes to Board
Marketwire (Wed, Nov 25)
MOLECULAR INSIGHT PHARMACEUTICALS, INC. Financials
EDGAR Online Financials (Sat, Nov 14)
More Headlines for MIPI...

 ANALYST 
EPS Est (next year) (Dec-09) :-2.93
EPS Est (in 2 years) (Dec-10) :-2.81
Avg Rec (current)*:1.7
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and c...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices